Literature DB >> 29954938

Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing.

Yanira Ruiz-Heredia1, Beatriz Sánchez-Vega1, Esther Onecha1, Santiago Barrio2, Rafael Alonso3, Jose Carlos Martínez-Ávila4, Isabel Cuenca1, Xabier Agirre5, Esteban Braggio6, Miguel-T Hernández7, Rafael Martínez8, Laura Rosiñol9, Norma Gutierrez10, Marisa Martin-Ramos9, Enrique M Ocio10, María-Asunción Echeveste11, Jaime Pérez de Oteyza12, Albert Oriol10, Joan Bargay13, Mercedes Gironella14, Rosa Ayala1, Joan Bladé15, María-Victoria Mateos10, Klaus M Kortum2, Keith Stewart6, Ramón García-Sanz10, Jesús San Miguel5, Juan José Lahuerta3, Joaquín Martinez-Lopez16.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29954938      PMCID： PMC6278988          DOI： 10.3324/haematol.2018.188839

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.

Authors:  Yuan Xiao Zhu; Esteban Braggio; Chang-Xin Shi; Laura A Bruins; Jessica E Schmidt; Scott Van Wier; Xiu-Bao Chang; Chad C Bjorklund; Rafael Fonseca; P Leif Bergsagel; Robert Z Orlowski; A Keith Stewart
Journal:  Blood       Date:  2011-08-22       Impact factor: 22.113

2.  Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project.

Authors:  H Avet-Loiseau; B G M Durie; M Cavo; M Attal; N Gutierrez; J Haessler; H Goldschmidt; R Hajek; J H Lee; O Sezer; B Barlogie; J Crowley; R Fonseca; N Testoni; F Ross; S V Rajkumar; P Sonneveld; J Lahuerta; P Moreau; G Morgan
Journal:  Leukemia       Date:  2012-10-03       Impact factor: 11.528

3.  Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk disease.

Authors:  Klaus M Kortüm; Christian Langer; Jorge Monge; Laura Bruins; Jan B Egan; Yuan X Zhu; Chang Xin Shi; Patrick Jedlowski; Jessica Schmidt; Juhi Ojha; Lars Bullinger; Peter Liebisch; Miriam Kull; Mia D Champion; Scott Van Wier; Gregory Ahmann; Leo Rasche; Stefan Knop; Rafael Fonseca; Hermann Einsele; A Keith Stewart; Esteban Braggio
Journal:  Br J Haematol       Date:  2014-10-10       Impact factor: 6.998

4.  A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial.

Authors:  K D Boyd; F M Ross; L Chiecchio; G P Dagrada; Z J Konn; W J Tapper; B A Walker; C P Wardell; W M Gregory; A J Szubert; S E Bell; J A Child; G H Jackson; F E Davies; G J Morgan
Journal:  Leukemia       Date:  2011-08-12       Impact factor: 11.528

5.  A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma.

Authors:  N Bolli; Y Li; V Sathiaseelan; K Raine; D Jones; P Ganly; F Cocito; G Bignell; M A Chapman; A S Sperling; K C Anderson; H Avet-Loiseau; S Minvielle; P J Campbell; N C Munshi
Journal:  Blood Cancer J       Date:  2016-09-02       Impact factor: 11.037

6.  Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients.

Authors:  K M Kortuem; E Braggio; L Bruins; S Barrio; C S Shi; Y X Zhu; R Tibes; D Viswanatha; P Votruba; G Ahmann; R Fonseca; P Jedlowski; I Schlam; S Kumar; P L Bergsagel; A K Stewart
Journal:  Blood Cancer J       Date:  2016-02-26       Impact factor: 11.037

7.  Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.

Authors:  Jens G Lohr; Petar Stojanov; Scott L Carter; Peter Cruz-Gordillo; Michael S Lawrence; Daniel Auclair; Carrie Sougnez; Birgit Knoechel; Joshua Gould; Gordon Saksena; Kristian Cibulskis; Aaron McKenna; Michael A Chapman; Ravid Straussman; Joan Levy; Louise M Perkins; Jonathan J Keats; Steven E Schumacher; Mara Rosenberg; Gad Getz; Todd R Golub
Journal:  Cancer Cell       Date:  2014-01-13       Impact factor: 31.743

8.  RUbioSeq: a suite of parallelized pipelines to automate exome variation and bisulfite-seq analyses.

Authors:  Miriam Rubio-Camarillo; Gonzalo Gómez-López; José M Fernández; Alfonso Valencia; David G Pisano
Journal:  Bioinformatics       Date:  2013-04-28       Impact factor: 6.937

9.  Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.

Authors:  Niccolo Bolli; Hervé Avet-Loiseau; David C Wedge; Peter Van Loo; Ludmil B Alexandrov; Inigo Martincorena; Kevin J Dawson; Francesco Iorio; Serena Nik-Zainal; Graham R Bignell; Jonathan W Hinton; Yilong Li; Jose M C Tubio; Stuart McLaren; Sarah O' Meara; Adam P Butler; Jon W Teague; Laura Mudie; Elizabeth Anderson; Naim Rashid; Yu-Tzu Tai; Masood A Shammas; Adam S Sperling; Mariateresa Fulciniti; Paul G Richardson; Giovanni Parmigiani; Florence Magrangeas; Stephane Minvielle; Philippe Moreau; Michel Attal; Thierry Facon; P Andrew Futreal; Kenneth C Anderson; Peter J Campbell; Nikhil C Munshi
Journal:  Nat Commun       Date:  2014       Impact factor: 14.919

10.  Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.

Authors:  Brian A Walker; Eileen M Boyle; Christopher P Wardell; Alex Murison; Dil B Begum; Nasrin M Dahir; Paula Z Proszek; David C Johnson; Martin F Kaiser; Lorenzo Melchor; Lauren I Aronson; Matthew Scales; Charlotte Pawlyn; Fabio Mirabella; John R Jones; Annamaria Brioli; Aneta Mikulasova; David A Cairns; Walter M Gregory; Ana Quartilho; Mark T Drayson; Nigel Russell; Gordon Cook; Graham H Jackson; Xavier Leleu; Faith E Davies; Gareth J Morgan
Journal:  J Clin Oncol       Date:  2015-08-17       Impact factor: 44.544
View more
  10 in total

1.  CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement.

Authors:  Matteo Claudio Da Vià; Antonio Giovanni Solimando; Andoni Garitano-Trojaola; Santiago Barrio; Umair Munawar; Susanne Strifler; Larissa Haertle; Nadine Rhodes; Eva Teufel; Cornelia Vogt; Constantin Lapa; Andreas Beilhack; Leo Rasche; Hermann Einsele; K Martin Kortüm
Journal:  Oncologist       Date:  2019-10-18

2.  The Dynamics of Nucleotide Variants in the Progression from Low-Intermediate Myeloma Precursor Conditions to Multiple Myeloma: Studying Serial Samples with a Targeted Sequencing Approach.

Authors:  Bénedith Oben; Charlotte Cosemans; Ellen Geerdens; Loes Linsen; Kimberly Vanhees; Brigitte Maes; Koen Theunissen; Bert Cruys; Marta Lionetti; Ingrid Arijs; Niccolò Bolli; Guy Froyen; Jean-Luc Rummens
Journal:  Cancers (Basel)       Date:  2022-02-18       Impact factor: 6.639

3.  CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement.

Authors:  Matteo Claudio Da Vià; Antonio Giovanni Solimando; Andoni Garitano-Trojaola; Santiago Barrio; Umair Munawar; Susanne Strifler; Larissa Haertle; Nadine Rhodes; Eva Teufel; Cornelia Vogt; Constantin Lapa; Andreas Beilhack; Leo Rasche; Hermann Einsele; K Martin Kortüm
Journal:  Oncologist       Date:  2019-10-18

4.  Germline CDKN1B Loss-of-Function Variants Cause Pediatric Cushing's Disease With or Without an MEN4 Phenotype.

Authors:  Fanny Chasseloup; Nathan Pankratz; John Lane; Fabio R Faucz; Margaret F Keil; Prashant Chittiboina; Denise M Kay; Tara Hussein Tayeb; Constantine A Stratakis; James L Mills; Laura C Hernández-Ramírez
Journal:  J Clin Endocrinol Metab       Date:  2020-06-01       Impact factor: 5.958

5.  Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide.

Authors:  Phoebe A Huang; Shaunna L Beedie; Cindy H Chau; David J Venzon; Sheryl Gere; Dickran Kazandjian; Neha Korde; Sham Mailankody; Ola Landgren; William D Figg
Journal:  Sci Rep       Date:  2019-10-16       Impact factor: 4.379

Review 6.  Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications.

Authors:  Ignacio J Cardona-Benavides; Cristina de Ramón; Norma C Gutiérrez
Journal:  Cells       Date:  2021-02-05       Impact factor: 6.600

Review 7.  Genome Instability in Multiple Myeloma: Facts and Factors.

Authors:  Anna Y Aksenova; Anna S Zhuk; Artem G Lada; Irina V Zotova; Elena I Stepchenkova; Ivan I Kostroma; Sergey V Gritsaev; Youri I Pavlov
Journal:  Cancers (Basel)       Date:  2021-11-26       Impact factor: 6.639

8.  Comparison of Clinical Characteristics and Genetic Aberrations of Plasma Cell Disorders in Thailand Population.

Authors:  Chutirat Jirabanditsakul; Sumana Dakeng; Chutima Kunacheewa; Yaowalak U-Pratya; Weerapat Owattanapanich
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

9.  Cereblon enhancer methylation and IMiD resistance in multiple myeloma.

Authors:  Larissa Haertle; Santiago Barrio; Umair Munawar; Seungbin Han; Xiang Zhou; Cornelia Vogt; Rafael Alonso Fernández; Max Bittrich; Yanira Ruiz-Heredia; Matteo Da Viá; Josip Zovko; Andoni Garitano-Trojaola; Niccolò Bolli; Anna Ruckdeschel; Thorsten Stühmer; Manik Chatterjee; Miriam Kull; Jan Krönke; Xabier Agirre; Jose I Martin-Subero; Peter Raab; Hermann Einsele; Leo Rasche; Joaquin Martinez-Lopez; Thomas Haaf; K Martin Kortüm
Journal:  Blood       Date:  2021-11-04       Impact factor: 22.113

Review 10.  Multiple myeloma with central nervous system relapse.

Authors:  Philip A Egan; Patrick T Elder; W Ian Deighan; Sheila J M O'Connor; H Denis Alexander
Journal:  Haematologica       Date:  2020-05-15       Impact factor: 9.941
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.